Optimization of pharmacotherapy with direct oral anticoagulants: The need to choose the right dosage regimen [Оптимизация фармакотерапии прямыми...
Кочетков А. И., Остроумова О. Д.
Рациональная фармакотерапия в кардиологии
Т. 15, Вып. 4, С. 593-603
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.20996/1819-6446-2019-15-4-593-603
Аннотация:
In recent years, there has been a persistent trend towards the more frequent prescription of direct oral anticoagulants (DOACs) compared with vitamin K antagonists due to the extensive body of evidence showing their high safety and efficacy, which in some cases exceed those of warfarin, and also by reason of there is no necessity for regular monitoring of international normalized ratio. However, the question of the reasonable and rational prescription of DOACs becomes relevant, including issues of their dosing, especially as a result of increasing in the number of patients with a complex cardiovascular risk profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high efficacy and safety both in full dose and reasonably reduced dosage has been proved, including older patients, patients with chronic kidney disease, coronary artery disease, with history of acute coronary syndrome and individuals undergoing percutaneous coronary intervention. This DOA
Ключевые слова:
Anticoagulant therapy; Apixaban; Cardiovascular risk; Comorbidity; Direct oral anticoagulants; Doses; Pharmacokinetics; Treatment adherence
apixaban; anticoagulant therapy; Article; drug efficacy; drug safety; drug use; evidence based medicine; human; patient compliance; renal clearance; systemic disease; thromboembolism
Язык текста: Русский
ISSN: 2225-3653
Кочетков А. И.
Остроумова О. Д. Ольга Дмитриевна 1968-
Kochetkov A. I.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Optimization of pharmacotherapy with direct oral anticoagulants: The need to choose the right dosage regimen [Оптимизация фармакотерапии прямыми оральными антикоагулянтами: необходимость правильного выбора режима дозирования]
Optimization of pharmacotherapy with direct oral anticoagulants: The need to choose the right dosage regimen [Оптимизация фармакотерапии прямыми...
Текст визуальный непосредственный
Рациональная фармакотерапия в кардиологии
Столичная издательская компания
Т. 15, Вып. 4 С. 593-603
2019
Статья
Anticoagulant therapy Apixaban Cardiovascular risk Comorbidity Direct oral anticoagulants Doses Pharmacokinetics Treatment adherence
apixaban anticoagulant therapy Article drug efficacy drug safety drug use evidence based medicine human patient compliance renal clearance systemic disease thromboembolism
In recent years, there has been a persistent trend towards the more frequent prescription of direct oral anticoagulants (DOACs) compared with vitamin K antagonists due to the extensive body of evidence showing their high safety and efficacy, which in some cases exceed those of warfarin, and also by reason of there is no necessity for regular monitoring of international normalized ratio. However, the question of the reasonable and rational prescription of DOACs becomes relevant, including issues of their dosing, especially as a result of increasing in the number of patients with a complex cardiovascular risk profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high efficacy and safety both in full dose and reasonably reduced dosage has been proved, including older patients, patients with chronic kidney disease, coronary artery disease, with history of acute coronary syndrome and individuals undergoing percutaneous coronary intervention. This DOA